vimarsana.com

Page 194 - மருத்துவ ரீதியாக ஒருங்கிணைந்த வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Welcome To IANS Live - LatestNews - Covaxin demonstrates interim clinical efficacy of 81%

Photo Credit: IANS IANSLive Hyderabad, March 3 (IANS) Bharat Biotech on Wednesday announced the first interim analysis of Covaxin, which shows the efficacy of the Covid-19 vaccine to be at 81 per cent. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 03-March-2021

6 stories making headlines this week

The Broadmoor Community Church Foundation has issued a challenge to faith-based organizations and others to increase donations of food and money to nonprofit organization Westside CARES, in light of increased

Role of nurses needs to be expanded in aged care reform

Date Time Role of nurses needs to be expanded in aged care reform The Australian College of Nursing (ACN) has welcomed the delivery of the final report of the Royal Commission into Aged Care Quality and Safety, saying that the Federal Government now has two clear roadmaps to reforming the sector. The Chief Executive Officer of the Australian College of Nursing, Adjunct Professor Kylie Ward FACN, said the historic final report delivered real opportunities for reform. “The Royal Commission has laid out two real templates for change, and it is now up to the Government to stand strong and deliver on one of these options,” Adjunct Professor Ward said.

ABIONYX Pharma: ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine

ABIONYX Pharma: ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine Confirmation of the breakthrough therapy status of CER-001 in kidney and ophthalmic diseases Systemic mechanism of action of CER-001 ABIONYX Pharma ( FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in the LCAT (lecithin-cholesterol acyltransferase) deficiency disease published in the Annals of Internal Medicine The patient with inherited mutations in the lecithin-cholesterol acyltransferase (LCAT) gene developed glomerulopathy and corneal lipid deposits and displayed very low circulating levels of high-density lipoprotein (HDL) and apoA-I. The patient was treated with CER-001, an apoA-I-containing HDL mimetic, to help in preventing rapidly progressive kidney failure.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.